COPD patients during acute attacks and remission show differences in serum cytokine concentrations and their clinical significance compared to the control group, with bodily performance reflecting a TH advantage status. The TH advantage state is evident before and after treatment, showing significant differences in the acute exacerbation of COPD before and after treatment, as well as the existence of a TH/TH superior state, which is directly related to changes in the levels of IL-4 and IFN-r f71. In recent years, research progress on the relationship between disease and TH/TH cellular immune response function has advanced rapidly. These preliminary studies illustrate the cytopathological and physiological effects of human TH/TH and provide a theoretical basis for the clinical treatment of TH or TH-mediated immune diseases. Finkelstein also observed that the number of T cells in the alveolar wall correlates with the extent of lung tissue damage. Studies both domestically and internationally have reported that glucocorticoids inhibit IL-4 expression and not only suppress IL-8 mRNA or IL-8 expression at the transcriptional and post-transcriptional levels but also inhibit the chemotaxis of neutrophil cells and eosinophils mediated by IL-8. Changes in the dominant state during the treatment of acute exacerbation of COPD, through the application of glucocorticoids, alleviate symptoms in COPD patients with TH/TH, reflecting different immune statuses. Based on the above results, various clinical methods can be employed to reverse the TH or TH dominant state to achieve treatment goals.